scholarly journals Bridge to ß Blockade in Severe Heart Failure: The Use of Phosphodiesterase Inhibitors

2000 ◽  
Vol 6 (3) ◽  
pp. 164-166 ◽  
Author(s):  
Khalid Muhammad ◽  
Hector O. Ventura ◽  
Dwight D. Stapleton ◽  
Frank W. Smart
1991 ◽  
Vol 29 (10) ◽  
pp. 39-40

Enoximone (Perfan – Merrell) and milrinone (Primacor – Sterling-Winthrop) are phosphodiesterase inhibitors marketed for short-term intravenous use in patients with heart failure on intensive care units. The manufacturers claim that enoximone is ‘a first-line inotrope for the failing heart’ while milrinone is advocated for ‘resistant heart failure’. Are these drugs useful additions to existing treatments?


Author(s):  
Abdallah Fayssoil ◽  
Djillali Annane

Inotropes are drugs commonly used in the intensive care unit. This class of agents includes a broad variety of molecules that improve cardiac index by increasing intracellular concentrations of cyclic AMP, or sensitivity to intracellular calcium, or by inhibiting the sodium/potassium pump. The main inotropic agents available are digoxin, catecholamines, and non-catecholergic drugs, e.g. phosphodiesterase inhibitors and levosimendan. In practice, dobutamine, a beta1 and beta2 agonist, is the inotrope of choice in patients with acute heart failure, or in patients with severe sepsis and evidence for left ventricle dysfunction. Levosimendan may be an alternative choice in patients with severe heart failure, particularly for those previously treated with beta-blockers. The main serious adverse events related to any inotrope are life-threatening arrhythmias.


2003 ◽  
Vol 2 (1) ◽  
pp. 108
Author(s):  
G DAN ◽  
A DAN ◽  
I DAHA ◽  
C STANESCU ◽  
V ILIE ◽  
...  

Chirurgia ◽  
2020 ◽  
Vol 33 (4) ◽  
Author(s):  
Yasunobu Konishi ◽  
Yoshimori Araki ◽  
Genta Takemura ◽  
Takafumi Terada ◽  
Osamu Kawaguchi

Sign in / Sign up

Export Citation Format

Share Document